Iopasentis (Iopamidol)

Iopamidol contains iodine atoms that absorb X‑ray photons strongly. After intra‑arterial or intravenous injection, it distributes in the vascular and extracellular compartments, creating a radiopaque field that differentiates structures on X‑ray‑based imaging, thereby allowing clinicians to see vessels and organs more clearly.

The dose of Iopasentis is determined by the prescribing physician based on the specific imaging study, patient weight, renal function, and clinical protocol. Healthcare providers calculate the appropriate volume and concentration to achieve optimal contrast enhancement while minimizing risk.

Iopasentis should be used in pregnancy or while breastfeeding only if the potential diagnostic benefit outweighs the possible risk to the fetus or infant. Clinicians should assess maternal and fetal health, consider alternative imaging methods, and discuss any concerns with the patient.

To order Iopasentis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Iopasentis contains iopamidol, a non‑ionic, low‑osmolality iodinated contrast medium. Compared with older high‑osmolality agents, it typically offers a lower incidence of adverse reactions and better patient tolerance, while providing comparable radiographic enhancement for angiography and CT imaging.

Iopasentis should be stored at temperatures below 25 °C, in its original sealed container, protected from light and moisture. Do not freeze the product. Before use, inspect the solution for particulate matter or discoloration and allow it to reach room temperature if refrigerated during transport.

Iopasentis is administered by a qualified healthcare professional via intra‑arterial or intravenous injection, typically using a power injector or manual bolus, according to the imaging protocol. The injection rate and volume are tailored to the specific diagnostic procedure and patient characteristics.

The most serious risks include severe allergic reactions (anaphylaxis), contrast‑induced nephropathy leading to acute kidney injury, significant hypotension or cardiovascular collapse, and rare thyroid dysfunction. Prompt recognition and management of these events are essential during and after administration.

Iopasentis is contraindicated in patients with a known hypersensitivity to iopamidol or any iodinated contrast media, those with uncontrolled severe asthma, and patients with unstable renal function where the risk of contrast‑induced nephropathy outweighs diagnostic benefit. Clinicians should evaluate each case individually.